CANC Tema Oncology ETF
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 40.13 | Day Range | 40.17 – 41.00 |
| 52-Week Range | 29.28 – 47.00 | Volume | 12.33K |
| Avg Volume | 32.79K | AUM | $201.5M (Oct 10, 2026) |
| Expense Ratio | 0.99% | Yield (TTM) | 0.05% |
| NAV | 40.07 | Premium/Discount | +1.78% indicative |
| Inception | Aug 14, 2023 | Holdings | 58 |
| Issuer | Tema | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 87975E701 | ISIN | US87975E7013 |
| Management | Not stated in source data | ||
About this ETF
The Tema Oncology ETF (CANC) is designed to strategically invest in companies well-positioned to capitalize on significant advancements within cancer-focused biotechnology and the broader healthcare sector.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -4.09% | -2.11% | +9.42% | +17.45% | +36.02% | +20.70% | — | — | +17.63% |
| Total return | -4.09% | -2.11% | +9.42% | +17.45% | +36.11% | +22.07% | — | — | +18.89% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.99% | Annual cost of a $10,000 investment | $99.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 58 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC | RVMD | 5.38% | 58.13K | $11.0M |
| 2 | MERCK & CO INC | MRK | 5.24% | 73.81K | $10.7M |
| 3 | COGENT BIOSCIENCES INC | COGT | 4.69% | 310.54K | $9.6M |
| 4 | ELI LILLY & CO | LLY | 4.62% | 8.03K | $9.5M |
| 5 | NOVARTIS AG | NOVN.SW | 3.78% | 54.07K | $7.8M |
| 6 | GENMAB A/S | GMAB | 3.68% | 203.74K | $7.6M |
| 7 | ABBVIE INC | ABBV | 3.59% | 26.61K | $7.4M |
| 8 | BEONE MEDICINES LTD | ONC | 3.47% | 20.09K | $7.1M |
| 9 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 3.37% | 472.17K | $6.9M |
| 10 | EXELIXIS INC | EXEL | 3.26% | 111.71K | $6.7M |
| 11 | HALOZYME THERAPEUTICS INC | HALO | 3.18% | 59.08K | $6.5M |
| 12 | BRISTOL-MYERS SQUIBB CO | BMY | 3.09% | 107.35K | $6.3M |
| 13 | BRIDGEBIO PHARMA INC | BBIO | 2.68% | 84.25K | $5.5M |
| 14 | ROCHE HOLDING AG | RHHBY | 2.66% | 100.72K | $5.4M |
| 15 | IDEAYA BIOSCIENCES INC | IDYA | 2.58% | 146.64K | $5.3M |
| 16 | IMMUNOME INC | IMNM | 2.52% | 264.81K | $5.2M |
| 17 | JOHNSON & JOHNSON | JNJ | 2.50% | 19.60K | $5.1M |
| 18 | CG ONCOLOGY INC | CGON | 2.49% | 79.92K | $5.1M |
| 19 | ENLIVEN THERAPEUTICS INC | ELVN | 2.33% | 116.58K | $4.8M |
| 20 | ERASCA INC | ERAS | 2.13% | 271.94K | $4.4M |
| 21 | ASTRAZENECA PLC | AZN.L | 2.07% | 26.78K | $4.3M |
| 22 | RELAY THERAPEUTICS INC | RLAY | 1.98% | 226.66K | $4.1M |
| 23 | ZAI LAB LTD | ZLAB | 1.88% | 154.51K | $3.9M |
| 24 | LEGEND BIOTECH CORP | LEGN | 1.85% | 204.01K | $3.8M |
| 25 | SUMMIT THERAPEUTICS INC | SMMT | 1.84% | 214.13K | $3.8M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.05% | Paid (last 12 months) | $0.0196 |
| Frequency | Annual | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Dec 10, 2025 | Last payment | $0.0196 (Dec 11, 2025) |
| Growth 1Y | -97.31% | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 10, 2025 | Dec 10, 2025 | Dec 11, 2025 | $0.0196 |
| Dec 11, 2024 | Dec 11, 2024 | Dec 12, 2024 | $0.7283 |
| Dec 13, 2023 | Dec 14, 2023 | Dec 15, 2023 | $0.1491 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 22.92% / 23.38% | Sharpe 1Y / 3Y | 1.66 / 0.929 |
| Max drawdown 1Y / 3Y | -11.29% / -28.04% | Sortino 1Y | 2.68 |
| Beta vs S&P 500 (3Y) | 0.78 | Correlation vs S&P 500 (1Y) | 0.406 |
| Downside deviation 1Y | 14.20% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 11, 2026. Formulas →
Liquidity
| Volume today | 12.33K | Average volume | 32.79K |
| AUM | $201.5M | Premium/Discount | +1.78% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$1.9M | -0.95% | $203.5M → $201.5M |
| 1 Month | -$3.0M | -1.44% | $208.3M → $201.5M |
| 1 Week | -$2.7M | -1.31% | $205.3M → $201.5M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for CANC
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.